Perspective Therapeutics Inc. Common Stock (CATX)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Perspective Therapeutics is a radiopharmaceutical developer with a Phase 1/2a candidate, VMT-a-NET, and 163 employees. The financial record is not that of a business yet. In fiscal Q2 2026, the quarter ended 2026-06-30, it lost $26.8 million, or $0.22 per diluted share. FY2025 losses were $103.1 million, or $1.40 per share, worse than FY2024's $79.3 million loss and FY2023's $46.5 million loss. The only revenue shown in the filed figures is $1.4 million in FY2023. Trailing free cash flow was negative $121.2 million, and the FairStock FCF yield was negative 46.8% against a $259.1 million market cap. That burn is enormous relative to the equity value. Debt is low, with a D/E of 0.01, but that does not create a moat. The FairStock Piotroski score is 1/9, its Altman Z-score is 1.52, ROE is -39.57%, and ROCE is -22.27%. P/B is 0.80 at the $2.27 close on 2026-10-13, but book value can evaporate through R&D. The FairStock P/E is -1.71. No Lynch category fits because it lost money each of the last four years. This is a clinical-stage option, not a Graham value stock. I would want proof of trial success and a financing runway before treating the price as cheap.

In plain English: Perspective Therapeutics is a radiopharmaceutical company trying to develop targeted alpha therapies to treat cancer. It has no recent product revenue in the filings and has been losing money, including a $26.8 million loss in the quarter ended 2026-06-30. At $2.27 on 2026-10-13, the price looks low compared with its accounting net worth, but the business is unprofitable and burning cash, so it does not look cheap on business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer